Researchers examine the effectiveness of coronavirus disease (COVID-19) vaccines approved in 2023-2024 and whether they continue to serve as the clinical standard to protect against the virus. I discovered that. The first COVID-19 vaccine approval was for Pfizer-BioNTech’s Comirnaty in August 2021. 1 Since then, state-of-the-art vaccines have been needed to protect the public from new coronavirus variants and the rise in cases during the winter months.
In a poster presented at IDWeek 2024, researchers take a deep dive into the COVID-19 vaccines that will be approved in 2023-2024. In addition to investigating the overall effectiveness of vaccines for prevention against COVID-19, they will investigate hospitalization rates, post-COVID-19 conditions, He also mentioned the effects of vaccines on fatigue. In addition, they studied the effects of two vaccines, the BNT162b2 COVID-19 vaccination and the XBB.1.5 variant. 2-6
Learn more about IDWeek here.
Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.
References 1. FDA approves first coronavirus vaccine. News release. F.D.A. August 23, 2021. Accessed October 10, 2024. https://www.fda.gov/news-events/press-payments/fda-approves-first-covid-19-vaccine2. Priddy F, McGhee N, Cholkias S, et al. Six-month safety, durability, and cross-neutralization of SARS-CoV-2 XBB.1.5-containing vaccines. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-102.3. Decuir J, Zhu Y, Johnson C et al. Updated efficacy of COVID-19 vaccines against COVID-19-related hospitalizations in adults in 2023-2024 (monovalent XBB.1.5) — IVY Network, 20 US states. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-2069.4. Yehoshua A, Yarnoff B, Di Fusco M, et al. Public health impact and economic value of additional doses of the Pfizer-BioNTech XBB.1.5-adapted COVID-19 vaccine to older adults in the United States. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-2047.5. Di Fusco M, Rudolph A, Lupton LL, et al. Efficacy of BNT162b2 COVID-19 vaccination against long-lasting COVID-19 in older adults: a nationwide study. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-2060.6. Six-month trajectory of symptoms of COVID-19 fatigue by age and BNT162b2 COVID-19 vaccination status: among symptomatic U.S. adults who tested positive for SARS-CoV-2 at a national retail pharmacy. A prospective study. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-1977.
Source link
